OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY

EHA Library, Shaji Kumar, 266363

MM-BMSCS INDUCE IMMUNOSENESCENT NAÏVE CD4+ T-CELLS THROUGH THE NOVEL INTERCELLULAR COMMUNICATION - TUNNELING NANOTUBES

EHA Library, Yadan Wang, 266364

INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY

EHA Library, Alejandra Ortiz, 266365

CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA

EHA Library, Raquel Ordoñez, 266366

INVESTIGATING MECHANISMS OF ELOTUZUMAB AND LENALIDOMIDE THERAPY IN MULTIPLE MYELOMA

EHA Library, Kelden J Richardson, 266367

CARFILZOMIB TREATMENT CAUSES RETICULOCYTOSIS BY IMPAIRING TERMINAL ERYTHROID MATURATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Nicolas Kint, 266369

IDENTIFICATION OF HLA-E AS A KEY GENE IN MULTIPLE MYELOMA BASED ON BIOINFORMATIC ANALYSIS AND DESIGN HIGH-AFFINITY PEPTIDES TARGETING HLA-E BASED ON COMPUTATIONAL TECHNIQUES

EHA Library, Ying Yang, 266370

ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA

EHA Library, Takuto Tachita, 266371

SINGLE CELL RNA-SEQ REVEALED A RARE ITGA2 EXPRESSING CELL SUBPOPULATION WITH DISTINCT CANCER STEM CELL MARKER SIGNATURE IN MULTIPLE MYELOMA

EHA Library, Margaret Heung-Ling Ng, 266372

TARGETED ULTRA-DEEP NGS ASSESSMENT OF TP53 MUTATIONS IN MULTIPLE MYELOMA FROM WHOLE BONE MARROW

EHA Library, Anna PETRACKOVA, 266373

OVEREXPRESSION DNP73 PROMOTES THE PROLIFERATION AND DRUG RESISTANCE OF MULTIPLE MYELOMA

EHA Library, Jie Xu, 266374

NONSENSE-MEDIATED MRNA DECAY IS A THERAPEUTIC TARGET IN MULTIPLE MYELOMA

EHA Library, Alexander Leeksma, 266375

TARGETING PROTEIN ARGININE METHYLTRANFERASE PRMT5 IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?

EHA Library, Ken Maes, 266376

THE BONE MARROW MICROENVIRONMENT OF MULTIPLE MYELOMA PROMOTES MYELOMA RELATED ANEMIA BY SUPPRESSING THE DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS

EHA Library, Lanting Liu, 266377

TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS` CHARACTERISTICS IN MULTIPLE MYELOMA.

EHA Library, Paola Omedé, 266378

PIWIL1 PROMOTES DRUG RESISTANCE IN MULTIPLE MYELOMA THROUGH MODULATING MITOPHAGY

EHA Library, Wu Qiuling, 266379

FUNCTIONAL HIGH-THROUGHPUT SCREENING FOR IDENTIFICATION OF NOTCH1 DOWNSTREAM EFFECTORS AS NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA

EHA Library, Daniela Maichl, 266380

PARTICIPATION OF IMMUNE RESPONSE GENES POLYMORPHISM IN THE OCCURRENCE OF SOLID TUMORS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Elena Nazarova, 266381

COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA

EHA Library, Arantxa Carrasco, 266382

C-MYC-DRIVEN AND PRMT5-DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE

EHA Library, Peipei Xu, 266383

GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY

EHA Library, Alessandra Romano, 266384

SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY

EHA Library, Alessandra Larocca, 266385

SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Christine Chen, 266386

SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

EHA Library, Rao Prabhala, 266387

MULTIPLE HIGH-RISK CYTOGENETIC ABERRATIONS CONFER A PROGRESSIVELY NEGATIVE IMPACT ON SURVIVALS OF NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Xue-Han Mao, 266388

MONITORING THE CYTOGENETIC ARCHITECTURE OF MINIMAL RESIDUAL PLASMA CELLS INDICATES THE THERAPY-INDUCED CLONAL SELECTION IN MULTIPLE MYELOMA.

EHA Library, Yuting Yan, 266389

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

EHA Library, Meletios A. Dimopoulos, 266390

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

EHA Library, Cyrille Hulin, 266391

THE IMPACT OF RESPONSE KINETICS FOLLOWING INITIAL THERAPY FOR MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, Yuting Yan, 266392

BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Laura Rosiñol, 266393

Pomalidomide + Bortezomib + Low-Dose Dexamethasone vs Bortezomib + Low-Dose Dexamethasone After One Prior Line of Therapy in Patients With Lenalidomide-Pretreated Multiple Myeloma: Subgroup Analysis of the Phase 3 OPTIMISMM Trial

EHA Library, Meletios Dimopoulos, 266394

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

EHA Library, Katja Weisel, 266395

HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL

EHA Library, Elias K. Mai, 266396

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

EHA Library, Cyrille Hulin, 266397

EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL

EHA Library, Elizabeth PHILLIPS, 266398

IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

EHA Library, Xue-Han Mao, 266399

EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY

EHA Library, Ajai Chari, 266400

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

EHA Library, Vittorio MONTEFUSCO, 266401

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

EHA Library, Aurore Perrot, 266402

THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB

EHA Library, Andrew Spencer, 266403

SYSTEMATIC LITERATURE REVIEW AND NETWORK-META ANALYSIS COMPARING INDUCTION TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE TRANSPLANT ELIGIBLE SETTING

EHA Library, John Ashcroft, 266404

ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA

EHA Library, Amani Erra, 266405

MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012-03).

EHA Library, Arthur Bobin, 266406

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

EHA Library, Ludek Pour, 266407

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT

EHA Library, Noemi Puig, 266408

OUTCOMES FOR TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE, OR BORTEZOMIB AND DEXAMETHASONE: AN ENHANCED DATABASE ANALYSIS

EHA Library, Ajai Chari, 266409

MULTIPLE DRUG COMBINATIONS FOR FIRST-LINE TREATMENT IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

EHA Library, Vanessa Piechotta, 266410

ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 266411

CLINICAL UTILITY OF [18F]FLORBETABEN PET/CT SCAN FOR IMAGING AMYLOIDOSIS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Jae-Cheol Jo, 266412

PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Alessandra Tedeschi, 266413

IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY

EHA Library, Laura Rosiñol, 266414

REAL-WORLD USE OF THE TRIPLET REGIMEN CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A SUB-GROUP INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Xavier Leleu, 266415

IMPACT OF EARLY VS LATE RELAPSE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A SUB ANALYSIS OF THE PHASE 3 FIRST TRIAL

EHA Library, Thierry Facon, 266416

PROGNOSTIC IMPACT OF 18F-FDG PET/CT IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH RENAL IMPAIRMENT

EHA Library, Je-Jung Lee, 266417

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE AS FIRST-LINE THERAPY IN TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: INTERIM RESULTS OF THE OBSERVATIONAL STUDY FIRST-NIS

EHA Library, Hans-Jürgen Hurtz, 266418

COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL

EHA Library, PARAMESWARAN HARI, 266419

REAL WORLD EXPERIENCE IN THE MANAGEMENT OF WALDENSTRÖM’S MACROGLOBULINAEMIA FROM ANALYSIS OF THE RORY MORRISON REGISTRY

EHA Library, Joshua BOMSZTYK, 266420

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 266421

PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

EHA Library, SHINSUKE IIDA, 266422

VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS

EHA Library, M Hasib Sidiqi, 266424

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3

EHA Library, Fredrik Schjesvold, 266425

SERUM CEREBLON LEVELS PREDICT FIVE- YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS.

EHA Library, Annita-Ioanna Gkioka, 266426

O-12-M1: AN EVALUATION OF TIME TO NEXT TREATMENT IN MELFLUFEN AND DEXAMETHASONE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sara Bringhen, 266427

CONSOLIDATION FOLLOWING INFUSIONAL DPACE IMPROVES OUTCOMES IN NOVEL AGENT RELAPSED/REFRACTORY MYELOMA PATIENTS

EHA Library, Faouzi Djebbari, 266428

MINIMAL RESIDUAL DISEASE MONITORING AND DEPTH OF RESPONSE IN MULTIPLE MYELOMA

EHA Library, Joaquin martinez-lopez, 266429

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

EHA Library, Donna Reece, 266430

EARLY SALVAGE TREATMENT WITH SECOND-GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL-WORLD SINGLE CENTER EXPERIENCE

EHA Library, Francesco Di Raimondo, 266431

PROGNOSTIC VALUE OF KIDNEY BIOPSY INTERSTITIAL FIBROSIS IN REVERSIBILITY OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY DUE TO MYELOMA CAST NEPHROPATHY

EHA Library, Evgeniia KAZARINA, 266432

OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM)

EHA Library, Louise Ainley, 266433

SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS

EHA Library, Hiroki Kobayashi, 266434

NATURAL KILLER CELL ALLOREACTIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS

EHA Library, Catharina Van Elssen, 266435

EFFICACY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL EVIDENCE

EHA Library, Thierry Facon, 266436

Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma

EHA Library, Keonwoo Yi, 266437

IMMUNE ELECTRON MICROSCOPY AND MASS SPECTROMETRY FOR CLASSIFICATION OF AMYLOID DEPOSITS

EHA Library, Niels Abildgaard, 266438

MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION-BASED “IDENTIFYING OUTCOMES IN REAL-WORLD MULTIPLE MYELOMA” (INFORMM) STUDY

EHA Library, Victor H. Jimenez-Zepeda, 266439

CHARACTERIZATION OF TREATMENTS AND REAL-LIFE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION IN SWEDEN

EHA Library, F Borgsten, 266440

REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS - A SINGLE CENTRE EXPERIENCE

EHA Library, Amanda Jurgensen-Rauch, 266441

CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Peter M. Voorhees, 266442

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP).

EHA Library, Anna Mele, 266443

EXPOSURE-RESPONSE ANALYSIS & DISEASE MODELING FOR SELECTION OF OPTIMAL DOSING REGIMEN OF ISATUXIMAB AS SINGLE AGENT IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Hoai Thu Thai, 266444

ASSOCIATION BETWEEN BORTEZOMIB CUMULATIVE DOSE AND TREATMENT-FREE INTERVAL IN TRANSPLANT-INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA

EHA Library, Jianming He, 266445

THE PROGNOSTIC IMPACT OF PATHOLOGIC FRACTURE AS MYELOMA-DEFINING EVENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Rafael Rios-Tamayo, 266446

TREATMENT PATTERNS FOR MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE COHORT STUDY IN U.S. ELECTRONIC MEDICAL RECORDS DATABASE 2012-2018

EHA Library, PARAMESWARAN HARI, 266447

ALPINA: REAL WORLD ANALYSIS OF 1ST LINE RVD TREATMENT IN TRANSPLANT ELIGIBLE AND TRANSPLANT-NON-ELIGIBLE MM PATIENTS WITH A FOCUS ON TOLERABILITY AND EFFICACY

EHA Library, Wolfgang Willenbacher, 266448

AGE DOES NOT CONFER DIFFERENT FEATURES AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED ACTIVE MULTIPLE MYELOMA YOUNGER THAN 66 YEARS OF AGE TREATED IN A RECENT PERIOD.

EHA Library, Eloísa Riva, 266449

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN A REAL LIFE SETTING: A SINGLE CENTER RETROSPECTIVE STUDY

EHA Library, Sabrina Trudel, 266450

EPIGENETIC ALTERATION OF CSK BINDING PROTEIN(CBP) IN MYELOPROLIFERATIVE NEOPLASMS COMPLEMENTS THE JAK2V617F MUTATION

EHA Library, Jian HUANG, 266453

PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS

EHA Library, Sebastiano Rontauroli, 266454

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Kristian BOASMAN, 266455

USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES

EHA Library, Gonzalo Carreno Gomez-Tarragona, 266456

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF EXPANSION OF MYELOID-DERIVED SUPPRESSOR CELLS IN MYELOFIBROSIS BEFORE AND AFTER TREATMENT WITH RUXOLITINIB: A SINGLE-CENTER EXPERIENCE

EHA Library, Alessandra Romano, 266457

MYELOMONOCYTIC SKEWING IN VITRO DISCRIMINATES SUBGROUPS OF PATIENTS WITH MYELOFIBROSIS WITH A DIFFERENT PHENOTYPE, A DIFFERENT GENOTYPE AND DIFFERENT PROGNOSIS

EHA Library, Klaus Geissler, 266458

TRANSCRIPTIONAL PROFILES OF PRIMARY CULTURES OF ERYTHROID AND MEGAKARYOCYTIC CELLS IN ESSENTIAL THROMBOCYTHEMIA UNCOVER A HIGH DEGREE OF GENE DEREGULATION IN THE MEGAKARYOCYTIC LINEAGE.

EHA Library, Petros Papadopoulos, 266459

MOLECULAR PROFILING REVEALS HIGHLY DEREGULATED INSULIN GROWTH FACTOR BINDING PROTEINS IN PATIENTS WITH MYELOFIBROSIS AND RELATED NEOPLASMS

EHA Library, Vibe Skov, 266460

MICRORNA EXPRESSION PROFILE IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS: THE IMPACT OF 3 MONTHS IMMUNE THERAPY USING PEGYLATED INTERFERON-ALPHA2.

EHA Library, Morten K Larsen, 266461

TRANSCRIPTION ALTERATION OF DNA REPAIR GENES IN PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Martin KIRSCHNER, 266462

46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS

EHA Library, Gonzalo Carreno Gomez-Tarragona, 266463

SERUM FERRITIN LEVELS ARE INCREASED IN IDIOPATHIC ERYTHROCYTOSIS BUT REDUCED IN POLYCYTHEMIA VERA

EHA Library, Giacomo Biagetti, 266464

LOW JAK2 V617F ALLELE BURDEN PHI-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS MAY ASSOCIATE WITH ADDITIONAL CALR OR MPL MUTATIONS.

EHA Library, Tatiana Makarik, 266465

THE ROLE OF HEPCIDIN AND DYSREGULATED IRON HOMEOSTASIS IN THE PATHOGENESIS OF ANEMIA IN MYELOFIBROSIS

EHA Library, Stela Dimitrova, 266466